CASPIAN Proves Too Choppy For AZ Imfinzi/Tremelimumab Combo
But Imfinzi Benefit Reinforced For Small Cell Lung Cancer
Another day and another fail for AstraZeneca's combination of Imfinzi and tremelimumab, this time for extensive-stage small-cell lung cancer.
You may also be interested in...
After five years of failure in NSCLC trials, AstraZeneca’s immunotherapy combo shows survival benefits in POSEIDON.
The company is getting more attention these days for its TIGIT inhibitor tiragolumab in combination with Tecentriq for 1L NSCLC, but a new 1L monotherapy indication for Tecentriq helps it compete against Keytruda.
In top-line final Phase III results from KEYNOTE-604, Keytruda improves PFS but not OS when combined with chemotherapy for the first-line treatment of small-cell lung cancer.